Article citationsMore>>
Scagliotti, G.V., Fossati, R., Torri, V., Crino, L., Giaccone, G., Silvano, G., Martelli, M., Clerici, M., Cognetti, F. and Tonato, M. (2003) Randomized Study of Adjuvant Chemotherapy for Completely Resected Stage I, II, or IIIA Non-Small-Cell Lung Cancer. Journal of the National Cancer Institute, 95, 1453-1461.
http://dx.doi.org/10.1093/jnci/djg059
has been cited by the following article:
-
TITLE:
Feasibility Study for Biweekly Administration of Cisplatin plus Vinorelbine as Adjuvant-Chemotherapy for Completely Resected Non-Small Cell Lung Cancer Patients in a Japanese Population
AUTHORS:
Shuichi Tsukamoto, Koji Yamazaki, Ryo Mori, Masakazu Katsura, Hidenori Kouso, Daigo Kawano, Chie Ushijima, Sadanori Takeo
KEYWORDS:
NSCLC; Adjuvant Chemotherapy; Cisplatin and Vinorelbine; Biweekly
JOURNAL NAME:
Advances in Lung Cancer,
Vol.3 No.1,
February
18,
2014
ABSTRACT:
Purpose: To evaluate the feasibility of
biweekly administration of cisplatin and vinorelbine as adjuvant chemotherapy
for patients with completely resected non-small cell lung cancer (NSCLC). Patients
and Methods: This was a single-arm, single-institutional study. Patients with
completely resected NSCLC (p-Stage IB-IIIA) with no previous chemotherapy or
radiotherapy were eligible. Simon’s optimal two-stage design was applied. Both
cisplatin (50 mg/m2) and vinorelbine (25 mg/m2) were
given on days 1 and 15, every 28 days. The primary endpoint of this study was
the feasibility of this combination in the four cycles of treatment. Results: Twenty patients (19 lobectomies and 1
pneumonectomy) were enrolled in this study. 10 (50%) of patients had
grade 3/4 neutropenia, and 3 (15%) had grade 3/4 anemia. Severe non-hematologic
toxicities were uncommon in this series. No treatment-related death was
encountered. 18 (90%) patients completed the planned 4 cycles of chemotherapy.
The median intensity was 24.3 (range 18.1 to 25) mg/m2/week with an
average of 23.6 (21 - 25) mg/m2/week cisplatin and 12.5
(range 10 to 12.5) mg/m2/week
with an average of 12.3 (10 - 12.5) mg/m2/week vinorelbine. The
median relative dose intensity of cisplatin was 97.5% (range 72.5% to 100%) with an average of 94.6% (72.5% - 100%) and that of vinorelbine was 100% (range 80% to 100%) with an average of 97.8% (80% - 100%). Conclusion: This regimen is feasible in the
treatment of patients with completely resected NSCLC. A phase III trial is warranted to assess the efficacy of this
regimen at promoting survival and preventing recurrence.
Related Articles:
-
Takanori Ayabe, Masaki Tomita, Kunihide Nakamura
-
Jamsheed Javid, Rashid Mir, Pramod Kumar Julka, Prakash Chandra Ray, Alpana Saxena
-
Hala Aziz Shokralla, Mohamed Rahouma
-
Jeyanthi Ramanarayanan, Ganapathy Krishnan
-
Ghada Ezzat Eladawei, Rasha Mohamed Abdellatif, Sheref Mohamed El-Taher